A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Active:	No
Cancer Type:	Hematopoietic Malignancies Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT03555955
Trial Phases:	Phase I	Protocol IDs:	CPX351-102 (primary) NCI-2019-00697
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Jazz Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT03555955

Summary

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or
severe renal impairment.

Treatment Sites in Georgia

Atlanta Cancer Care - Conyers
1498 Klondike Road
Suite 106
Conyers, GA 30094
404-303-3355
www.atlantacancercare.com

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:

Stacey Brown
404-780-7965

Doctors:

Asad Bashey MD, PhD

H. Kent Holland MD

Lawrence E. Morris, Jr. MD

Scott R. Solomon MD

Melhem Solh MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.